Somnomed Limited · ASX:SOM
Somnomed — FY2025 Earnings Presentation
21 slides from Somnomed's earnings presentation, August 2025
Slide 1: Investor Presentation Full Year 2025 Results
Investor Presentation Full Year 2025 Results August 2025 Treatment focused. Technology driven.
Slide 2: Disclaimer
Disclaimer This document has been prepared as a summary only and does not contain all information about SomnoMed Limited’s (the Company’s) assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s securities. This document
Slide 3: FY25 Results
FY25 Results 1. FY25 Highlights 2. Financials 3. Operations update 4. FY26 outlook
Slide 4: FY25 Highlights
FY25 Highlights Revenue EBITDA1 Capex $111.5m $9.2m $4.0m +22% vs pcp2 vs pcp of vs pcp of of $91.7m $0.6m $5.3m vs. guidance of $105m vs. guidance of $7-9m vs. guidance of $3-4m Cash balance Operating cash Free cash $17.3m flow flow4 +7% vs pcp of $4.8m3 $0.8m $16.2m vs pcp of ($8.9m) vs pcp of ($1
Slide 5: Building the foundations for profitable growth
Building the foundations for profitable growth Execution & Delivery People & culture Build a high performing team • Hired key new leadership and culture of efficiency and • Board refresh providing further Execution and sector, manufacturing delivery improvement and investment experience Financial Ge
Slide 6: FY25 Results
FY25 Results 1. FY25 Highlights 2. Financials 3. Operations update 4. FY26 outlook
Slide 7: Double digit growth across all regions
Double digit growth across all regions New management commenced FY24 H2 +22% Revenue growth • Achieved $100m revenue milestone. +10% • Revenue growth of +22% vs pcp. • Double digit growth across all regions. +15% • Delivered revenue of $111.5m vs guidance of $105m. Earnings growth • EBITDA1 of $9.2m
Slide 8: Regional revenue highlights
Regional revenue highlights Europe North America APAC +17% $61m $52m +31% +23% $43m +11% $33m $33m +32% +30% $28m $27m $25m $22m $21m +11% $17m $16m +5% +16% $6m $7m $3m $4m $3m $3m 1H 2H FY 1H 2H FY 1H 2H FY FY24 FY25 FY24 FY25 FY24 FY25 © August 2025 SomnoMed 8
Slide 9: Profit or loss summary
Profit or loss summary $m FY25 FY24 % Revenue • Double digits growth across all regions. Revenue 111.5 91.7 +22% • Driven by robust overall demand and continued capacity Gross margin 66.7 55.1 +21% uplifts, reduction in turn around time and backlog. Sales and marketing expenses (22.9) (24.5) (7%) Ad
Slide 10: Gross margins
Gross margins (10)% 70% Strategic margin investment 60% Managed Care services generate additional revenue and drive device volumes while creating operational leverage. Device GM Managed Care GM Dilution Total GM • High-margin core oral devices • Lower margin services that create • Total gross margin
Slide 11: Balance sheet summary
Balance sheet summary $m 30 June 2025 30 June 2024 Cash Cash and cash equivalents 17.3 16.2 • Increased balance sheet strength with positive Trade and other receivables 18.5 12.4 operating cash flow $4.8m1 and free cash flow $0.8m, +$13.7m and $15.1m vs pcp, respectively. Inventories 7.4 6.3 Propert
Slide 12: Cash flow summary
Cash flow summary $m FY25 FY24 EBITDA1 9.2 0.6 Movement in working capital and other non-cash (0.1) (0.9) Tax paid (0.8) (1.1) One-off expenses Net finance costs paid - (1.6) • Relates to payments of one-off cost provisions. One-off expenses (0.5) (3.0) Operating cash flow 7.8 (6.1) (1.6) (4.0) Inve
Slide 13: FY25 Results
FY25 Results 1. FY25 Highlights 2. Financials 3. Operations update 4. FY26 outlook
Slide 14: FY25 Operational Highlights
FY25 Operational Highlights Rest Assure® Successful 1 million FDA cleared for manufacturing patients compliance overhaul treated monitoring New Global management tenders team success & Board renewal © August 2025 SomnoMed 14
Slide 15: Rest Assure Progress FY25 and FY26 Planned Objectives
Rest Assure® Progress FY25 • FDA cleared Rest Assure® as the first oral device with built-in compliance monitoring. • Clearance includes the oral device and software platform incl. patient app, physician platform, docking station and cloud systems. • Clinical validation paper published - “this devic
Slide 16: FY25 Results
FY25 Results 1. FY25 Highlights 2. Financials 3. Operations update 4. FY26 outlook
Slide 17: SomnoMed's Opportunity
SomnoMed's Opportunity VISION INVESTMENT HIGHLIGHTS A world where our oral appliance Significant total addressable market with 900+ million individuals therapy is the standard of care for sleep suffering from OSA globally. apnea treatment. Increasing consumer awareness, growth in GLP-1 drugs, and de
Slide 18: Strategy and Outlook
Strategy and Outlook FY25 FY26 FY27 and beyond Execution and Sustainable Stabilisation and delivery – year of growth and innovation reset investment • Financial: >10+% EBITDA1 People and culture: build a high • Financial: sustainable revenue margins performing team and culture of and margin growth
Slide 19: FY26 guidance
FY26 guidance Revenue EBITDA1 Capex2 $119m-$126m $10m-$12m $6m-$8m vs. $91.7m FY24 vs. $0.6m FY24 1 EBITDA excludes leases payments of between $3m-$3.5m, share/option expenses, unrealised foreign exchange gain/(loss), one-off costs and discontinued operations. 2 Capex spend expected to approximate 2
Slide 20: Q&A
Q&A
Slide 21: Thank You
Thank You For further information please contact: Investor Relations: IR@somnomed.com.au © August 2025 SomnoMed 21